Under exceptional (emergency use) status, Japan’s Ministry of Health, Labor and Welfare has approved Gilead Sciences’ (GILD +0.4%) remdesivir, branded as Veklury, for the treatment of severely ill COVID-19 patients.
https://seekingalpha.com/news/3571333-gilead-confirms-remdesivir-approval-in-japan-for-severe-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.